Amexdrug Corporation (AXRX)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Amexdrug Corporation (AXRX) trades at $0.00. Amexdrug Corporation distributes pharmaceutical products and manufactures health and beauty items. Market cap: $33,882, Sector: Healthcare.
Last analyzed: Mar 16, 2026Analyst Coverage for AXRX: AXRX does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates AXRX against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
AXRX: 1/1 perspectives are bearish.
Amexdrug Corporation (AXRX) Healthcare & Pipeline Overview
Amexdrug Corporation, founded in 1963, operates in the pharmaceutical and cosmeceutical sectors, distributing drugs and manufacturing health & beauty products. Targeting independent pharmacies and smaller chains in California, the company markets products under the Sponix brand, with a current market capitalization of $0.00B and a negative P/E ratio.
What Is the Investment Thesis for AXRX?
Amexdrug Corporation presents a challenging investment case given its negative P/E ratio of -5.00 and a market capitalization of $0.00B. The company's gross margin stands at 33.1%, while its profit margin is -0.2%. A key factor to consider is the company's focus on the California market and its reliance on independent pharmacies. Future growth hinges on expanding its product lines and distribution network beyond its current scope. Investors should closely monitor the company's ability to improve profitability and manage its operational costs. The company's beta of -0.54 suggests a lower volatility compared to the market.
Based on FMP financials and quantitative analysis
AXRX Key Highlights
- Market capitalization of $0.00B, indicating a micro-cap status.
- Negative P/E ratio of -5.00, reflecting current losses.
- Gross margin of 33.1%, suggesting some efficiency in production costs.
- Profit margin of -0.2%, indicating challenges in achieving overall profitability.
- Beta of -0.54, suggesting lower volatility compared to the broader market.
Who Are AXRX's Competitors?
Who Are AXRX's Competitors?
AXRX is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| MLPH Molecular Pharmacology (USA), Ltd. | $0.00 | +0.00% | 112K | 45 |
| ALVO Alvotech | $3.36 | +3.59% | $1.05B | 69 |
| KIN Kindred Biosciences, Inc. | $9.25 | +0.11% | 68 | |
| AERI Aerie Pharmaceuticals, Inc. | $15.25 | +0.00% | 68 | |
| MPXOF MPX International Corporation | $0.00 | +0.00% | 2K | 68 |
| AGRX Agile Therapeutics, Inc. | $1.51 | +3.42% | 11M | 59 |
| KHRNF Khiron Life Sciences Corp. | $0.00 | +0.00% | 2K | 59 |
| EGRX Eagle Pharmaceuticals, Inc. | $0.36 | -82.11% | $4.80M | 60 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are AXRX's Key Strengths?
- Established presence in the California market.
- Diversified product portfolio including pharmaceuticals and cosmeceuticals.
- Private labeling capabilities.
- Distribution network targeting independent pharmacies.
What Are AXRX's Weaknesses?
- Limited geographic reach, primarily focused on California.
- Small size and limited resources compared to larger competitors.
- Negative profit margin indicating financial challenges.
- Dependence on independent pharmacies, which may have limited purchasing power.
What Could Drive AXRX Stock Higher?
- Potential expansion into new geographic markets by 2027-2029 could drive revenue growth.
- Strategic partnerships with larger pharmaceutical companies could provide access to new resources and markets.
- Launch of an online sales channel by 2027 could broaden customer reach.
- Expansion of private label manufacturing activities provides a diversified revenue stream.
What Are the Key Risks for AXRX?
- Intense competition from larger pharmaceutical and cosmeceutical companies could limit market share.
- Changes in healthcare regulations and reimbursement rates could negatively impact profitability.
- Economic downturn affecting consumer spending on health and beauty products could reduce sales.
- Limited geographic reach, primarily focused on California, restricts growth potential.
- Negative profit margin indicates financial instability.
What Are the Growth Opportunities for AXRX?
- Geographic Expansion: Amexdrug can expand its distribution network beyond California to other states. By targeting regions with similar demographics and pharmacy landscapes, Amexdrug could increase its revenue streams. The market size for pharmaceuticals in the US is substantial, estimated at hundreds of billions of dollars annually, providing ample opportunity for growth if Amexdrug can effectively penetrate new markets. Timeline: 2027-2029.
- Product Line Diversification: Amexdrug can diversify its product offerings within the health and beauty segment. Developing new formulations, targeting specific skin conditions, or expanding into related product categories like sun care or anti-aging could attract new customers and increase sales. The global cosmeceuticals market is projected to reach billions of dollars, offering a significant growth avenue. Timeline: 2026-2028.
- Strategic Partnerships: Amexdrug can form strategic partnerships with larger pharmaceutical companies or distributors to leverage their resources and market reach. Collaborating on product development, manufacturing, or distribution could provide access to new technologies, markets, and expertise. The pharmaceutical industry is characterized by numerous collaborations, making this a viable growth strategy. Timeline: Ongoing.
- Online Sales Channel: Amexdrug can establish an online sales channel to reach a broader customer base. By creating an e-commerce platform, Amexdrug can sell its products directly to consumers, bypassing traditional retail channels. The online pharmacy market is experiencing rapid growth, driven by convenience and accessibility. Timeline: 2027.
- Private Label Manufacturing: Amexdrug can expand its private label manufacturing activities. By producing products for other companies, Amexdrug can increase its production volume and revenue without incurring additional marketing expenses. The private label market is a significant segment within the pharmaceutical and cosmeceutical industries, offering a steady stream of revenue. Timeline: Ongoing.
What Opportunities Does AXRX Have?
- Expansion into new geographic markets.
- Development of new and innovative health and beauty products.
- Strategic partnerships with larger pharmaceutical companies.
- Growth in the online pharmacy market.
What Threats Does AXRX Face?
- Intense competition from larger pharmaceutical and cosmeceutical companies.
- Pricing pressures from generic drugs.
- Changes in healthcare regulations and reimbursement rates.
- Economic downturn affecting consumer spending on health and beauty products.
What Are AXRX's Competitive Advantages?
- Established relationships with independent pharmacies in California.
- Proprietary formulations for certain health and beauty products.
- Private labeling capabilities offer a diversified revenue stream.
What Does AXRX Do?
Amexdrug Corporation, established in 1963, initially operated as Harlyn Products, Inc., before rebranding in April 2000 to reflect its shift towards pharmaceutical product sales. Headquartered in Commerce, California, the company functions as a pharmaceutical and cosmeceutical entity, engaging in the distribution, research, development, manufacture, and sale of pharmaceutical drugs, cosmetics, and medical devices. Amexdrug operates through two segments: Distribution and Health and Beauty Products. The Distribution segment focuses on prescription and over-the-counter drugs, non-drug products, and health and beauty items. The Health and Beauty Products segment manufactures and sells facial and body creams, arthritic pain relief medications, and hair and nail care products. Amexdrug markets its products under the Sponix brand, distributing primarily to independent pharmacies and secondarily to small-sized pharmacy chains, alternative care facilities, and other wholesalers and retailers, primarily within California. The company employs 9 individuals.
What Products and Services Does AXRX Offer?
- Distributes prescription drugs to independent pharmacies.
- Distributes over-the-counter drugs to independent pharmacies.
- Manufactures facial and body creams.
- Manufactures arthritic pain relief medications.
- Manufactures hair and nail care products.
- Engages in private manufacturing and labeling activities.
- Sells health and beauty products to beauty salons and stores.
How Does AXRX Make Money?
- Generates revenue through the distribution of pharmaceutical products.
- Generates revenue through the sale of manufactured health and beauty products.
- Generates revenue through private labeling and manufacturing agreements.
What Industry Does AXRX Operate In?
Amexdrug Corporation operates within the specialty and generic drug manufacturing industry, a segment characterized by intense competition and pricing pressures. Companies in this sector face challenges related to research and development costs, regulatory approvals, and generic erosion. Amexdrug's focus on distributing to independent pharmacies and smaller chains in California positions it within a niche market, but also limits its growth potential compared to larger, more diversified players. The industry is also affected by trends in healthcare policy, reimbursement rates, and consumer preferences for over-the-counter and cosmetic products.
Who Are AXRX's Key Customers?
- Independent pharmacies in California.
- Small-sized pharmacy chains in California.
- Beauty salons and beauty supply stores.
- Alternative care facilities.
- Wholesalers and retailers.
AXRX Financials
AXRX Latest News
No recent news available for AXRX.
AXRX Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for AXRX.
Price Targets
Wall Street price target analysis for AXRX.
AXRX MoonshotScore
What does this score mean?
The MoonshotScore rates AXRX's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Jack Amin
CEO
Jack Amin serves as the CEO of Amexdrug Corporation, leading a team of 9 employees. His background includes experience in the pharmaceutical and cosmeceutical industries. Prior to his role at Amexdrug, Amin held various positions in sales and marketing within the healthcare sector. He has a strong understanding of the distribution channels and market dynamics within the California region. Amin's leadership focuses on driving product innovation and expanding the company's market presence.
Track Record: Under Jack Amin's leadership, Amexdrug Corporation has focused on maintaining its distribution network within California and expanding its private labeling activities. Key strategic decisions have included streamlining operations to improve efficiency and investing in new product development. Amin has overseen the introduction of new health and beauty products to cater to changing consumer preferences. However, the company still faces challenges in achieving profitability.
AXRX OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Amexdrug Corporation may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited or no financial disclosure, making it difficult for investors to assess their financial health and operational performance. Investing in companies on the OTC Other tier carries a higher degree of risk compared to those listed on major exchanges like NYSE or NASDAQ due to the lack of regulatory oversight and transparency.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure and transparency.
- Potential for price manipulation due to low trading volume.
- Higher risk of fraud or misrepresentation.
- Lack of regulatory oversight compared to major exchanges.
- Limited access to company information and management.
- Verify the company's registration and legal status.
- Obtain and review any available financial statements.
- Assess the company's business model and competitive landscape.
- Research the background and experience of the management team.
- Evaluate the company's compliance with regulatory requirements.
- Understand the risks associated with investing in OTC stocks.
- Consult with a qualified financial advisor.
- Company has been in operation since 1963.
- Operates in the regulated pharmaceutical and cosmeceutical industries.
- Focuses on distribution to independent pharmacies, suggesting established relationships.
- Manufactures its own line of health and beauty products under the Sponix brand.
What Investors Ask About Amexdrug Corporation (AXRX) — Healthcare
What does Amexdrug Corporation do?
Amexdrug Corporation operates as a pharmaceutical and cosmeceutical company, primarily focusing on the distribution of pharmaceutical products and the manufacture of health and beauty items. It distributes prescription and over-the-counter drugs, along with non-drug and health & beauty products, mainly to independent pharmacies and smaller chains in California. Additionally, Amexdrug manufactures and sells its own line of facial creams, pain relief medications, and hair/nail care products under the Sponix brand, catering to pharmacies, beauty salons, and other retailers.
What do analysts say about AXRX stock?
As of 2026-03-16, formal analyst ratings for AXRX are unavailable due to its OTC listing and small market capitalization. Investors should conduct their own due diligence and consider the company's financial metrics, including its negative P/E ratio and modest gross margin. The company's growth potential hinges on its ability to expand beyond its current geographic focus and improve profitability. The OTC market carries inherent risks that should be carefully evaluated.
What are the main risks for AXRX?
Amexdrug Corporation faces several risks, including intense competition from larger pharmaceutical and cosmeceutical companies, which could limit its market share and pricing power. Its limited geographic reach, primarily focused on California, restricts its growth potential. Changes in healthcare regulations and reimbursement rates could also negatively impact its profitability. Additionally, the company's negative profit margin indicates financial instability and reliance on external funding, increasing its vulnerability to economic downturns.
What are the key factors to evaluate for AXRX?
Evaluating AXRX involves reviewing fundamentals, analyst consensus, and risk factors. Key strength: Established presence in the California market. Primary risk to monitor: Intense competition from larger pharmaceutical and cosmeceutical companies could limit market share. This is not financial advice.
How frequently does AXRX data refresh on this page?
AXRX prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven AXRX's recent stock price performance?
Recent price movement in Amexdrug Corporation (AXRX) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Established presence in the California market. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider AXRX overvalued or undervalued right now?
Determining whether Amexdrug Corporation (AXRX) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying AXRX?
Before investing in Amexdrug Corporation (AXRX), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited information available for OTC-listed companies.
- Financial data based on available information and may not be comprehensive.